Skip to Content
Merck
All Photos(1)

Documents

T4580

Sigma-Aldrich

Tiludronate disodium salt hydrate

≥98% (HPLC)

Synonym(s):

Skelid, Tiludronic acid disodium, [[(4-Chlorophenyl)thio]methylene]bisphosphonic acid disodium salt hydrate

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C7H7ClNa2O6P2S · xH2O
CAS Number:
89987-06-4
Molecular Weight:
362.57 (anhydrous basis)
MDL number:
MFCD16872037
UNSPSC Code:
12352200
PubChem Substance ID:
329826798
NACRES:
NA.77

Assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to off-white

solubility

H2O: >10 mg/mL, clear

originator

Sanofi Aventis

SMILES string

O.[Na+].[Na+].OP([O-])(=O)C(Sc1ccc(Cl)cc1)P(O)([O-])=O

InChI

1S/C7H9ClO6P2S.2Na.H2O/c8-5-1-3-6(4-2-5)17-7(15(9,10)11)16(12,13)14;;;/h1-4,7H,(H2,9,10,11)(H2,12,13,14);;;1H2/q;2*+1;/p-2

InChI key

SZVJRJRMQCKFON-UHFFFAOYSA-L

Related Categories

Biochem/physiol Actions

Tiludronate is a bisphosphonate bone resorption inhibitor. Tiludronate inhibits protein-tyrosine-phosphatase, leading to detachment of osteoclasts from the bone surface. It also inhibits the osteoclastic proton pump and is used to treat Paget′s disease.

Features and Benefits

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Preparation Note

Tiludronate disodium salt hydrate is soluble in DMSO at a concentration that is greater than or equal to 10 mg/ml.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Patricia Pascaud et al.
Langmuir : the ACS journal of surfaces and colloids, 29(7), 2224-2232 (2013-01-16)
Bisphosphonates (BPs) are well established as successful antiresorptive agents for the prevention and treatment of bone diseases such as osteoporosis and Paget's disease. The aim of this work was to clarify the reaction mechanisms between a BP molecule, tiludronate, and
Jean-Pierre Pelletier et al.
The Journal of rheumatology, 38(1), 118-128 (2010-10-19)
to investigate over a 1-year period in dogs that underwent extracapsular stabilization surgery (ECS) following anterior cruciate ligament (ACL) transection: whether reconstructive surgery could prevent osteoarthritis (OA) progression and whether treatment with the bisphosphonate tiludronic acid (TA) could improve the
L Alvarez et al.
Rheumatology (Oxford, England), 43(7), 869-874 (2004-04-01)
To monitor the long-term evolution of Paget's disease activity after treatment with tiludronate by using serum total alkaline phosphatase (TAP) and more sensitive markers such as bone alkaline phosphatase (BAP), procollagen type I N propeptide (PINP) and urinary N-terminal cross-linking
C Delguste et al.
Journal of veterinary pharmacology and therapeutics, 31(2), 108-116 (2008-03-01)
Bioavailability and pharmacological effects of tiludronate were compared when administered as an intravenous (i.v.) bolus at a dosage of 0.1 mg/kg body weight (b.w.) once daily for 10 consecutive days (group 1, n = 6) and as a single constant
C Delguste et al.
Bone, 41(3), 414-421 (2007-07-03)
Tiludronate, a bisphosphonate, has recently been introduced in veterinary medicine to treat orthopedic conditions in the horse. This study was designed to evaluate its effects on biochemical biomarkers of bone metabolism and on bone density and structure in an experimental
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service